Repurposing Clinically Safe Drugs to Guide DNA Repair in CRISPR Genome Editing

Study Background and Research Question

Genome editing technologies, particularly CRISPR-Cas9, have revolutionized the ability to introduce precise genetic modifications for research, disease modeling, and therapeutic applications. Central to the utility and safety of genome editing is the cell’s response to double-strand DNA breaks (DSBs), which can be repaired via several competing pathways: non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway yields distinct genetic outcomes, with NHEJ and MMEJ typically resulting in small insertions or deletions, and HDR enabling precise sequence changes using a template. However, the relative contribution of each pathway is influenced by cell type, cell cycle stage, and local DNA sequence context. A major limitation in the field has been the lack of tools to pharmacologically steer DSB repair pathway choice, which would enable both more controlled gene editing and new strategies for synthetic lethality in cancer. The study by Macak, Kanis, and Riesenberg (Nature Communications, 2025) addresses whether clinically approved drugs can be repurposed to modulate DSB repair outcomes in human cells, with the potential to enhance the precision and applicability of CRISPR-based interventions.

Key Innovation from the Reference Study

The central innovation of the reference paper is a systematic, high-throughput screening of over 7,000 clinically safe, FDA-approved compounds for their ability to influence DNA repair pathway choice following CRISPR-induced DSBs in human induced pluripotent stem cells (hiPSCs). This approach moves beyond genetic manipulation or introduction of exogenous proteins to identify small-molecule modulators that are already characterized for clinical use, thus lowering translational barriers. By quantifying mutational outcomes at a defined CRISPR target site (FRMD7) under drug treatment, the authors could distinguish compounds that enhance or suppress NHEJ, MMEJ, or HDR repair. Importantly, the work also highlights synergistic effects, such as increased HDR rates when combining pathway inhibitors with genetic silencing of key repair regulators like ESR2. This resource enables targeted editing strategies and suggests new synthetic lethality combinations for precision oncology.

Methods and Experimental Design Insights

The study employed a robust and scalable drug screening workflow. Human iPSCs expressing a doxycycline-inducible Cas9 (iCRISPR) system were treated with individual drugs during CRISPR-mediated targeting of the FRMD7 locus. Following a recovery period, cell survival was measured using a resazurin fluorescence assay, and genomic DNA was extracted for high-throughput Illumina sequencing to profile editing outcomes. Editing events were classified according to the type of repair pathway utilized:

• NHEJ events (typically 1-bp insertions)
• MMEJ events (deletions with ≥2 bp of microhomology)
• HDR events (precise edits using an exogenous template)

The experimental design allowed for the identification of compounds that shift the balance between these repair pathways. The study also included genetic perturbations (e.g., ESR2 and AOX1 silencing) to probe combinatorial effects with pharmacological agents.

Protocol Parameters

• Drug treatment: Apply individual FDA-approved drugs at concentrations optimized for cell viability; typically 10 μM unless cytotoxicity is observed.
• CRISPR editing: Use doxycycline-inducible Cas9 expression to target the desired genomic locus during drug exposure.
• Post-editing recovery: Allow 48–72 hours in normal media before analysis for optimal cell survival and DNA repair outcome assessment.
• Sequencing analysis: Use amplicon-based Illumina sequencing to quantify indel distributions and HDR rates at the target site.
• Genetic silencing (for synergy studies): Apply siRNA or CRISPRi to suppress genes such as ESR2 or AOX1 alongside drug treatment.

Core Findings and Why They Matter

The high-throughput screen revealed that several clinically approved compounds can modulate the choice of DSB repair pathway after CRISPR editing. Notably:

• Some drugs selectively increased HDR frequencies, improving the precision of template-directed genome editing.
• Other compounds inhibited NHEJ or MMEJ, biasing repair toward alternate pathways.
• Silencing ESR2 in combination with NHEJ inhibition led to a synergistic, 4.6-fold increase in HDR efficiency (reference study).
• Several drugs induced synthetic lethality when cells were genetically or pharmacologically deficient in specific repair pathways, suggesting new strategies for selective cancer cell targeting.

These findings have significant implications:

• For gene editing, pathway modulation can reduce undesired indels and large deletions, enhancing the safety and predictability of therapeutic interventions.
• For oncology, the identification of synthetic lethality-inducing drugs supports precision medicine approaches that exploit tumor-specific DNA repair deficiencies.
• The resource of drug-pathway interactions can accelerate disease modeling and genome-wide screening efforts in human cells.

Comparison with Existing Internal Articles

Recent internal reviews, such as "Repurposing Drugs to Modulate DNA Repair in CRISPR Editing", echo the reference study’s core message: systematic drug screening is a powerful lever for controlling DNA repair outcomes in genome editing. Both the reference and internal articles highlight the potential to use well-characterized drugs to enhance editing precision and synthetic lethality strategies—key for both disease modeling and translational therapeutics. From a biochemical perspective, intracellular calcium signaling has emerged as another modifiable axis in genome editing workflows. Compounds like dantrolene sodium salt, a potent ryanodine receptor antagonist, have been validated in the literature (see internal review) for their ability to modulate calcium release, which intersects with DNA damage response and cell viability in some contexts. While the reference study did not focus on calcium signaling, the mechanism-based use of such compounds can complement DNA repair pathway modulation in sophisticated experimental designs.

Limitations and Transferability

The most significant limitations of the study lie in its reliance on a single cell type (hiPSCs) and a defined CRISPR target locus. While the resource is comprehensive, pathway choice and drug efficacy may differ in primary cells, differentiated tissues, or in vivo models. Drug concentrations used for screening may not always be directly translatable to other systems, and off-target pharmacological effects require further characterization. Furthermore, while the screening identifies promising candidates for pathway modulation, mechanistic dissection of drug action (especially for compounds with pleiotropic effects) will be necessary for clinical translation. The synthetic lethality findings, though robust in cell culture, must be validated in disease-relevant settings to confirm therapeutic potential.

Why this cross-domain matters, maturity, and limitations

The study bridges pharmacology and genome engineering by leveraging clinically characterized drugs to control fundamental repair processes in CRISPR editing. This cross-domain approach accelerates translation: drugs with established safety profiles can be rapidly integrated into genome editing protocols and cancer therapy regimens. However, further work is needed to confirm that the observed pathway modulation holds across diverse genetic backgrounds and physiological contexts.

Research Support Resources

For researchers aiming to implement pathway modulation or calcium signaling control in CRISPR or synthetic lethality studies, high-purity and mechanistically validated reagents are essential. Dantrolene, sodium salt (SKU B6329) is a nanomolar-potency ryanodine receptor antagonist that enables precise modulation of intracellular calcium release, with proven utility in disease modeling and viability assays (see internal review). Its calmodulin-dependent specificity and high purity support reproducibility in complex experimental workflows. For details and protocols, refer to the product dossier and validated literature.